Paper Details

  1. Home
  2. Paper Details

Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.

Author: BielefeldtKlaus, GawronAndrew J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the frequency of pancreatitis attributed to eluxadoline, a drug used to treat diarrhea-predominant irritable bowel syndrome, in postmarketing surveillance. The study found that pancreatitis accounted for 16.4% of adverse event reports linked to eluxadoline, with at least half of these cases requiring hospitalization.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: The Food and Drug Administration approved eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome despite cases of pancreatitis in early stage trials. We investigated the frequency of pancreatitis attributed to eluxadoline in postmarketing surveillance. MET...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cgh.2017.08.006

データ提供：米国国立医学図書館（NLM）

Eluxadoline: A Question of Pancreatitis Risk

This research delves into the realm of [irritable bowel syndrome (IBS)] and examines the safety of a medication called [eluxadoline]. It highlights the potential risk of [pancreatitis] associated with eluxadoline, a concern that emerged during [postmarketing surveillance]. The authors analyzed data from the [Federal Adverse Event Reporting System] to investigate the frequency of pancreatitis reports linked to eluxadoline.

Pancreatitis Risk: A Cause for Concern?

The findings reveal that [pancreatitis] accounted for a significant proportion of adverse event reports associated with eluxadoline. A concerning number of these cases required hospitalization, highlighting the potential severity of this side effect. The authors compared the data with other antidiarrheals, oxycodone, and rifaximin, finding a significantly higher proportion of pancreatitis reports linked to eluxadoline.

Navigating the Desert of IBS Treatment

This research raises important questions regarding the safety of eluxadoline for treating IBS. It underscores the need for careful monitoring of patients prescribed this medication and emphasizes the importance of weighing the potential risks and benefits. It's like navigating a vast desert of IBS treatment options, where the choice of the right medication is crucial for a safe and successful journey.

Dr.Camel's Conclusion

This study confirms a previously reported risk of pancreatitis associated with eluxadoline. The high rate of hospitalization and recent reports of fatalities should prompt reassessment of the drug's risk-benefit ratio. Further investigation is needed to better understand the mechanisms underlying this potential side effect.

Date :
  1. Date Completed 2019-11-06
  2. Date Revised 2019-11-06
Further Info :

Pubmed ID

28804032

DOI: Digital Object Identifier

10.1016/j.cgh.2017.08.006

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.